- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel CD20 monoclonal antibodies for lymphoma therapy ; volume:5 ; number:1 ; day:11 ; month:10 ; year:2012 ; pages:1-9 ; date:12.2012
Journal of hematology & oncology ; 5, Heft 1 (11.10.2012), 1-9, 12.2012
- Urheber
-
Cang, Shundong
Mukhi, Nikhil
Wang, Kemeng
Liu, Delong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-5-64
- URN
-
urn:nbn:de:101:1-2021082419350410420911
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cang, Shundong
- Mukhi, Nikhil
- Wang, Kemeng
- Liu, Delong
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
An update on newer monoclonal antibodies in lymphoma therapy
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Monoclonal antibodies
Antibody-mediated direct killing and senolytic capacity of two distinct anti-CD20 monoclonal antibodies in human diffuse large B-cell lymphoma cell lines
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
An update on newer monoclonal antibodies in lymphoma therapy
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Monoclonal antibodies
Antibody-mediated direct killing and senolytic capacity of two distinct anti-CD20 monoclonal antibodies in human diffuse large B-cell lymphoma cell lines
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
An update on newer monoclonal antibodies in lymphoma therapy
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Monoclonal antibodies
Antibody-mediated direct killing and senolytic capacity of two distinct anti-CD20 monoclonal antibodies in human diffuse large B-cell lymphoma cell lines
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice